Roth Capital Has Bullish Estimate for Beyond Air Q3 Earnings

Beyond Air, Inc. (NASDAQ:XAIR) – Stock analysts at Roth Capital raised their Q3 2025 EPS estimates for shares of Beyond Air in a research report issued on Tuesday, November 12th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($0.23) for the quarter, up from their previous estimate of ($0.27). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Beyond Air’s current full-year earnings is ($0.92) per share. Roth Capital also issued estimates for Beyond Air’s Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.53) EPS.

Beyond Air (NASDAQ:XAIR) last announced its quarterly earnings data on Monday, November 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $1.19 million. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same period in the previous year, the business posted ($0.51) EPS.

Other equities research analysts have also issued reports about the stock. Piper Sandler dropped their target price on shares of Beyond Air from $3.50 to $1.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Roth Mkm reaffirmed a “buy” rating and set a $2.00 target price on shares of Beyond Air in a report on Friday, August 16th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Beyond Air has a consensus rating of “Buy” and an average target price of $3.67.

Beyond Air Price Performance

NASDAQ XAIR opened at $0.53 on Friday. The company’s 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $0.68. The company has a current ratio of 5.76, a quick ratio of 2.42 and a debt-to-equity ratio of 0.37. Beyond Air has a 1 year low of $0.30 and a 1 year high of $2.36.

Institutional Trading of Beyond Air

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Beyond Air in the 2nd quarter valued at $47,000. Vanguard Group Inc. increased its holdings in shares of Beyond Air by 5.0% in the first quarter. Vanguard Group Inc. now owns 1,399,298 shares of the company’s stock worth $2,435,000 after purchasing an additional 66,224 shares during the last quarter. Finally, Gendell Jeffrey L lifted its position in shares of Beyond Air by 30.4% in the first quarter. Gendell Jeffrey L now owns 1,461,071 shares of the company’s stock worth $2,542,000 after buying an additional 340,774 shares in the last quarter. Institutional investors own 31.50% of the company’s stock.

Insider Buying and Selling

In related news, CEO Steven A. Lisi purchased 1,476,626 shares of Beyond Air stock in a transaction dated Thursday, September 26th. The stock was purchased at an average cost of $0.50 per share, for a total transaction of $738,313.00. Following the completion of the purchase, the chief executive officer now directly owns 3,249,411 shares of the company’s stock, valued at $1,624,705.50. The trade was a 83.29 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 20.10% of the stock is currently owned by company insiders.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.